Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Artenimol SCHEMBL14552892 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL16404831 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL19236349 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL19600821 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL18421801 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL23843510 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL2132158 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL21707299 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL21707301 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 | |
| Artenimol SCHEMBL16638334 | 1.00 | PTGES2 (1.00) | PTGES2ALDH1A1LMNAHTTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220323472-A1 | ANTI-PARASITIC COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES | SPALLITTA FRANK ANTHONY (US) | 2022-10-13 | — | — | US | claimed |
| WO-2022212399-A1 | ANTI-PARASITIC COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES | SPALLITTA FRANK ANTHONY (US) | 2022-10-06 | — | — | WO | claimed |
| CN-110452252-B | Dihydroartemisinin semicarbazone/thiosemicarbazone phenol derivative, and synthesis method and application thereof | 西南大学 | 2022-06-24 | — | — | CN | claimed |
| EP-4746962-A1 | DIHYDROARTEMISININ DERIVATIVES AND THE TREATMENT OF FIBROTIC DISEASES | Greenstone Biosciences, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3493811-B1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS THAT REDUCE THE INCIDENCE OF INTRACEREBRAL HEMORRHAGE AND BRAIN MICROHEMORRHAGES | ZEBRAPEUTICS INC (CA) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025244856-A1 | METHODS AND COMPOSITIONS RELATING TO ELQ COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4536639-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | Oregon Health & Science University (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025069235-A1 | COMPOUND, PHOTOSENSITIVE SURFACE TREATMENT AGENT, LAMINATE PRODUCTION METHOD, AND TRANSISTOR PRODUCTION METHOD | 株式会社ニコン | 2025-04-03 | — | — | WO | disclosed |
| WO-2025019703-A1 | DIHYDROARTEMISININ DERIVATIVES AND THE TREATMENT OF FIBROTIC DISEASES | GreenStone Biosciences, Inc. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20240382448-A1 | METHODS FOR TREATING CORONAVIRUS INFECTION | BIOGENESYS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240317774-A1 | Pharmaceutical Compound | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| US-20220227779-A1 | METHOD FOR PREPARING DIHYDROARTEMISININ BULK DRUG IN SINGLE PROCESS | Zhangjiagang Vinsce Bio-pharm Co., Ltd. (CN) | 2022-07-21 | — | — | US | disclosed |
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| CN-113956990-B | Recombinant saccharomyces cerevisiae for producing dihydronilotinib as well as preparation method and application thereof | 中国中医科学院中药研究所 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022049867-A1 | TUMOR IMMUNE MICROENVIRONMENT REGULATOR, AND PREVENTIVE, DIAGNOSTIC OR THERAPEUTIC USE THEREOF | 国立大学法人東京大学 | 2022-03-10 | — | — | WO | disclosed |
| CN-113956990-A | Recombinant saccharomyces cerevisiae for producing dihydronilotinib as well as preparation method and application thereof | 中国中医科学院中药研究所 | 2022-01-21 | — | — | CN | disclosed |
| US-20200345770-A1 | Combination Therapy for Treatment of Leukemia | City, University of London (GB) | 2020-11-05 | — | — | US | disclosed |
| US-10292991-B2 | Small molecule therapeutic compounds that reduce the incidence of intracerebral hemorrhage and brain microhemorrhages | UNITY HEALTH TORONTO (CA) | 2019-05-21 | — | — | US | disclosed |
| US-20180064731-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS THAT REDUCE THE INCIDENCE OF INTRACEREBRAL HEMORRHAGE AND BRAIN MICROHEMORRHAGES | ZEBRAPEUTICS INC. (CA) | 2018-03-08 | — | — | US | disclosed |
| US-20180064731-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS THAT REDUCE THE INCIDENCE OF INTRACEREBRAL HEMORRHAGE AND BRAIN MICROHEMORRHAGES | ZEBRAPEUTICS INC. (CA) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323472-A1 | ANTI-PARASITIC COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES | CTSA, DDT, CTSV | PTGES2 3596/4885ALDH1A1 837/4885LMNA 1948/4885 |
| US-20200345770-A1 | Combination Therapy for Treatment of Leukemia | MCL1, AS3MT, MLLT3 | PTGES2 2068/4885ALDH1A1 239/4885LMNA 2393/4885 |
| US-20180064731-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS THAT REDUCE THE INCIDENCE OF INTRACEREBRAL HEMORRHAGE AND BRAIN MICROHEMORRHAGES | TFPI2, DCX, F13B | PTGES2 676/4885ALDH1A1 2580/4885LMNA 2162/4885 |
| US-20240317774-A1 | Pharmaceutical Compound | ABCB11, MAN2B1, CYP11B2 | PTGES2 2257/4885ALDH1A1 1628/4885LMNA 3511/4885 |
| US-10292991-B2 | Small molecule therapeutic compounds that reduce the incidence of intracerebral hemorrhage and brain microhemorrhages | TFPI2, DCX, F13B | PTGES2 676/4885ALDH1A1 2580/4885LMNA 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.